Crossmark

Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis

Crossref DOI link: https://doi.org/10.1038/S41598-018-24303-4

Published: 2018-12

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

Authors

Biondini, Davide

Balestro, Elisabetta

Lacedonia, Donato

Cerri, Stefania

Milaneschi, Rosanna

Luppi, Fabrizio

Cocconcelli, Elisabetta

Bazzan, Erica

Clini, Enrico http://orcid.org/0000-0002-1515-5094
Foschino Barbaro, Maria Pia

Gregori, Dario

Cosio, Manuel G

Saetta, Marina

Spagnolo, Paolo
License Information

Text and Data Mining valid from 2018-04-13
More Information

Article History

Received: 12 January 2018

Accepted: 27 March 2018

First Online: 13 April 2018

Competing Interests

: PS reports personal fees from Roche/Genentech, personal fees from InterMune, personal fees and non-financial support from Boehringer-Ingelheim, personal fees from Novartis, personal fees from Santhera Pharmaceuticals, outside the submitted work. MS reports grants from Takeda, grants from Guidotti, outside the submitted work. SC reports personal fees from Roche, personal fees from Boehringer Ingelheim, outside the submitted work. FL reports personal fees from Boehringer-Ingelheim, grants and personal fees from Roche, outside the submitted work. The remaining authors report no conflicts of interest.